MacDiarmid Scott A
Alliance Urology Specialists, Bladder Control and Pelvic Pain Center, 509 N. Elam Avenue, Greensboro, NC 27403, USA.
Curr Urol Rep. 2007 Sep;8(5):364-9. doi: 10.1007/s11934-007-0032-6.
Antimuscarinics are the treatment of choice for patients suffering from overactive bladder syndrome (OAB). Clinical experience and the literature support the efficacy, tolerability, and safety of each agent. With increasing data and educational and marketing efforts, many health care providers are uncertain which antimuscarinic should be prescribed first. It is important to recognize that there is not one superior agent, and that the individual response to each antimuscarinic is highly variable. This paper uses peer-reviewed literature to elucidate various agents with respect to efficacy, tolerability, and safety, to help readers understand the pros and cons associated with each drug so they may better manage patients with OAB.
抗毒蕈碱药物是治疗膀胱过度活动症(OAB)患者的首选药物。临床经验和文献均支持每种药物的疗效、耐受性和安全性。随着数据的增加以及教育和营销力度的加大,许多医疗保健提供者不确定应首先开具哪种抗毒蕈碱药物。必须认识到,没有一种药物是 superior 的,而且个体对每种抗毒蕈碱药物的反应差异很大。本文利用同行评审文献阐述了各种药物在疗效、耐受性和安全性方面的情况,以帮助读者了解每种药物的优缺点,从而更好地管理 OAB 患者。